News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Alexion Pharmaceuticals Inc. Q1 Profit Beats Street on Higher Soliris Sales
April 23, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters - Alexion Pharmaceuticals Inc (ALXN.O) posted better-than-expected quarterly earnings as revenue from its genetic-disorder drug Soliris jumped 78 percent.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Alexion
MORE ON THIS TOPIC
Business
Phase III Fail Forces Neuphoria Into Strategic Review—With One Investor Offering a Takeover
November 12, 2025
·
1 min read
·
Tristan Manalac
Layoffs
Kezar Loses 70% of Staff After FDA Cancels Meeting on Autoimmune Asset
November 10, 2025
·
2 min read
·
Dan Samorodnitsky
Layoff Tracker
Catalent’s Announced Cuts in Maryland This Year Now Total Over 400 Employees
November 10, 2025
·
78 min read
·
BioSpace Editorial Staff
Obesity
Despite Obesity Drug Pricing Deal, GLP-1 Compounders Continue To Operate in the Shadows
November 10, 2025
·
3 min read
·
Dan Samorodnitsky
